Clinical study reveals that early immune activation after single-dose trastuzumab correlates with pathologic response in HER2-positive breast cancer, highlighting useful predictive biomarkers.
Correlations between pCR rates, increases in Immune Index and markers of T-cell activity following brief exposure to trastuzumab in HER2-enriched tumors provide novel insights into the interaction between tumor biology, antitumor immunity, and response to treatment, and suggest potential clinically useful biomarkers in HER2(+) breast cancers. Clin Cancer Res; 22(13); 3249-59.
No takes yet. Share an insight, caveat, or question.
Varadan et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: